New hope for kids with rare lung scarring: long-term drug safety trial completed
NCT ID NCT05285982
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study looked at the long-term safety of a medicine called nintedanib in children and teenagers (ages 6-17) with a lung condition that causes scarring (fibrosing interstitial lung disease). All participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The goal was to see how well the drug is tolerated over time. The study included 54 participants and has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Meyer
Florence, 50139, Italy
-
BC Children's Hospital
Vancouver, British Columbia, V6H 3N1, Canada
-
Brussels - UNIV HUDERF
Brussels, 1020, Belgium
-
Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP
São Paulo, 5403-900, Brazil
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15224, United States
-
Clinical Research Institute S.C.
Tlalnepantla, 54055, Mexico
-
General Hospital of Thessaloniki "Ippokrateio"
Thessaloniki, 54642, Greece
-
HOP Intercommunal
Créteil, 94010, France
-
Hamburger Zentrum für Kinder- und Jugendrheumatologie
Hamburg, 22081, Germany
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Hospital Virgen del Rocío
Seville, 41013, Spain
-
Hospital de Niños Dr. Ricardo Gutierrez
CABA, C1425EFD, Argentina
-
Hospital de Pediatria Prof. Dr. Juan P. Garrahan
CABA, C1245AAM, Argentina
-
Independent Public Teaching Children's Hospital
Warsaw, 02091, Poland
-
King's College Hospital
London, SE5 9RS, United Kingdom
-
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, N-0372, Norway
-
Osp. Pediatrico Bambin Gesù
Roma, 00165, Italy
-
Serviços Medicos Respirar Sul Fluminense
Barra Mansa, 27323240, Brazil
-
Tampere University Hospital
Tampere, 33520, Finland
-
Teaching Hospital Motol, Oncology Clinic
Prague, 150 06, Czechia
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
ULS de Santa Maria, E.P.E
Lisbon, 1649-035, Portugal
-
ULS de São José, E.P.E. - Hospital Dona Estefânia
Lisbon, 1169-045, Portugal
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Weill Cornell Medicine-New York-60569
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.